# relapsed or refractory FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-or-refractory

> No upcoming FDA catalysts in relapsed or refractory; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for relapsed or refractory?

No upcoming FDA catalysts in relapsed or refractory; 5 past events are recorded. Press release filed with the SEC (EX-99): "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." [Calendar and source filings](https://sec-api.dev/indications/relapsed-or-refractory)

Source: Press release filed with the SEC (EX-99), accession 0001434265-25-000095, https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm (retrieved 2026-11-12). Last confirmed 2025-11-18. Cite: https://sec-api.dev/indications/relapsed-or-refractory#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2025 | [KOMZIFTI (ziftomenib) PDUFA date](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | scheduled | "FDA Priority Review of New Drug Application for ziftomenib with PDUFA target action date of November 30, 2025 - In June 2025, Kura and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced the U.S. Food and Drug Administration (FDA) accepted Kura's NDA seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (NPM1-m)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| June 1, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA acceptance](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed | "On June 1, 2025, Kura Oncology, Inc. (the "Company") and Kyowa Kirin Co., Ltd. ("Kyowa Kirin") announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's New Drug Application ("NDA") seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a nucleophosmin 1 ("NPM1") mutation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1422143/000119312525133717/d917067d8k.htm)) |
| October 24, 2025 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | relapsed or refractory | completed, approved | "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm)) |
| November 13, 2025 | [KOMZIFTI (ziftomenib) FDA approval](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed, approved | "Komzifti \| ziftomenib \| 11/13/2025 \| To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| November 18, 2025 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | GMAB | relapsed or refractory | completed, approved | "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm)) |

## Drugs

- [KOMZIFTI (ziftomenib)](https://sec-api.dev/pdufa/ziftomenib) (KURA)
- [Revuforj® (revumenib)](https://sec-api.dev/pdufa/revumenib) (SNDX)
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-or-refractory.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "relapsed or refractory FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-or-refractory

```bibtex
@misc{secapidev_indications_relapsed_or_refractory_20261116,
  title        = {relapsed or refractory FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-or-refractory}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_or_refractory_20261116","title":"relapsed or refractory FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-or-refractory","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
